Oculis (NASDAQ:OCS) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Oculis (NASDAQ:OCSFree Report) in a report issued on Thursday, Benzinga reports. HC Wainwright currently has a $28.00 price target on the stock.

OCS has been the topic of a number of other reports. Chardan Capital restated a buy rating and issued a $30.00 price target on shares of Oculis in a report on Tuesday, March 19th. Wedbush reaffirmed an outperform rating and set a $29.00 target price on shares of Oculis in a research report on Wednesday, March 6th. Finally, Robert W. Baird lowered their price target on Oculis from $64.00 to $35.00 and set an outperform rating for the company in a report on Tuesday, March 19th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of Buy and a consensus target price of $30.17.

Check Out Our Latest Report on Oculis

Oculis Stock Up 0.6 %

Shares of OCS opened at $11.76 on Thursday. The company has a quick ratio of 4.71, a current ratio of 4.71 and a debt-to-equity ratio of 0.01. Oculis has a 52-week low of $9.05 and a 52-week high of $14.50. The company has a market cap of $476.33 million, a PE ratio of -6.61 and a beta of 0.53. The business has a fifty day moving average of $11.94 and a 200 day moving average of $11.63.

Oculis (NASDAQ:OCSGet Free Report) last released its earnings results on Wednesday, May 8th. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.03). Oculis had a negative net margin of 6,712.02% and a negative return on equity of 52.72%. The business had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.28 million. On average, sell-side analysts expect that Oculis will post -1.84 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Wolverine Asset Management LLC purchased a new position in shares of Oculis during the third quarter worth $77,000. Searle & CO. purchased a new position in shares of Oculis during the 4th quarter valued at about $112,000. Compagnie Lombard Odier SCmA lifted its holdings in shares of Oculis by 47.3% in the 4th quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock valued at $1,053,000 after buying an additional 30,750 shares during the period. Finally, abrdn plc purchased a new stake in shares of Oculis in the fourth quarter worth about $15,980,000. 22.30% of the stock is owned by institutional investors and hedge funds.

About Oculis

(Get Free Report)

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

See Also

Analyst Recommendations for Oculis (NASDAQ:OCS)

Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.